Document is current
Any future updates will be listed below
-
Authors
Shi, Xiaoqian
Wang, Zhenyan
Ding, Fangping
Ma, Runlin Z.
Wang, Jing
Ma, Yingmin
Jin, Jiawei
-
Funding
Funding for this research was provided by:
National Natural Science Foundation of China (82400106)
National Natural Science Foundation of China (81770062)
Natural Science Foundation of Beijing Municipality (7214233)
Natural Science Foundation of Beijing Municipality (7252053)
Cultivation Program (Natural Sciences) of Capital Medical University grant (PYZ22083)
- License Information
-
More Information
Article History
Received: 18 June 2025
Accepted: 19 January 2026
First Online: 9 February 2026
Declarations
:
: For human samples: all studies involving human lung tissues were approved by the Ethics Committee of Beijing Chao-Yang Hospital (2021-KE-295) and signed informed consent for research use of samples were obtained from all subjects. All methods were carried out in accordance with relevant guidelines and regulations including the Code of Ethics of the World Medical Association (Declaration of Helsinki).For mouse study: all animal procedures were approved by the Animal Care and Ethics Committee of Beijing Chao-Yang Hospital (2021-Dong-11) and the Institute of Genetics and Developmental Biology, Chinese Academy of Sciences. The procedures were in accordance with the Guide for the Care and Use of Laboratory Animals of the Chinese Academy of Sciences.
: Not applicable.
: X.S., Z.W. and J.J. are inventors of a Chinese patent application for the glycosylation modification site of secreted RCN3 protein and its application.
